Extracorporeal albumin dialysis for acute liver failure (HTG202, formerly IPG316)

What this platform has drawn from it — 4 claims

• NICE found that evidence on extracorporeal albumin dialysis for acute liver failure raises no major safety concerns but that current evidence on its efficacy is inadequate in quality and quantity, and therefore restricted the procedure to use with special arrangements for clinical governance, consent and audit or research. Section 1 Recommendations, recommendation 1.1 · Section 1 Recommendations, recommendation 1.1, restriction clause
  read on Extracorporeal liver support
• NICE places a duty on clinicians undertaking extracorporeal albumin dialysis for acute liver failure to ensure that patients and their carers understand the uncertainty about the procedure's efficacy and to provide clear written information, subject to the requirement for an emergency procedure. Section 1 Recommendations, recommendation 1.2, second bullet
  read on Extracorporeal liver support
• NICE describes extracorporeal albumin dialysis as a procedure that aims to support the patient until either their own liver function recovers or a transplant becomes available, removing toxins bound to albumin in the blood in addition to the water-soluble toxins that haemodialysis can remove. Section 2 The procedure, 2.2 Outline of the procedure, 2.2.1
  read on Extracorporeal liver support
• In the evidence NICE considered, a meta-analysis reported no significant difference in 30-day all-cause mortality between patients who had extracorporeal albumin dialysis and those who had standard medical treatment. Section 2 The procedure, 2.3 Efficacy, 2.3.1
  read on Extracorporeal liver support